HUP0401076A2 - Alpha-2b-adrenoceptor antagonist compounds and their use for preparation of pharmaceutical compositions - Google Patents
Alpha-2b-adrenoceptor antagonist compounds and their use for preparation of pharmaceutical compositionsInfo
- Publication number
- HUP0401076A2 HUP0401076A2 HU0401076A HUP0401076A HUP0401076A2 HU P0401076 A2 HUP0401076 A2 HU P0401076A2 HU 0401076 A HU0401076 A HU 0401076A HU P0401076 A HUP0401076 A HU P0401076A HU P0401076 A2 HUP0401076 A2 HU P0401076A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alpha
- optionally mono
- disubstituted
- straight
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940122859 Alpha 2b adrenoceptor antagonist Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- -1 trifluoromethoxybenzyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 102000008841 Alpha 2B adrenoceptor Human genes 0.000 abstract 1
- 108050000738 Alpha 2B adrenoceptor Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány (I) általános képletű vegyületek és gyógyászatilagelfogadható sóikra, valamint ezeknek emlősöknél az alfa-2B-adrenoceptor által közvetített megbetegedések kezelésére vagymegelőzésére alkalmas gyógyászati készítmények előállítására valóalkalmazására vonatkozik. Az (I) általános képletben Rl , R2 , R3 , R4és R5 egymástól függetlenül hidrogén- vagy halogénatomot vagy egyenesvagy elágazó láncú alkil- vagy alkoxicsoportot jelent; X jelentésehidrogénatom, egyenes vagy elágazó láncú alkilcsoport, fenilcsoportvagy hidroxilcsoport; Z jelentése hidrogénatom, acetilcsoport,trifluormetoxibenzilcsoport vagy trifluormetilbenzilcsoport; Yjelentése a molekula további részéhez adott esetben 1 vagy 2szénatomot tartalmazó alkillánccal kapcsolt gyűrűs szerkezet,mimellett ez a gyűrűs szerkezet a) adott esetben mono- vagydiszubsztituált fenilcsoport; b) 2-benzimidazolil-, 2-imidazolil- vagy2- vagy 3-indolilcsoport, ahol az egyik nitrogénatom adott esetbenszubsztituálva lehet; (c) adott esetben mono- vagy diszubsztituáltpiridinilcsoport; vagy (d) adott esetben mono- vagy diszubsztituáltnaftilcsoport. ÓThe invention relates to compounds of general formula (I) and their pharmaceutically acceptable salts, as well as their use in the production of pharmaceutical preparations suitable for the treatment or prevention of diseases mediated by the alpha-2B-adrenoceptor in mammals. In the general formula (I), R1 , R2 , R3 , R4 and R5 independently represent a hydrogen or halogen atom or a straight or branched chain alkyl or alkoxy group; X represents a hydrogen atom, a straight or branched alkyl group, a phenyl group or a hydroxyl group; Z represents a hydrogen atom, an acetyl group, a trifluoromethoxybenzyl group or a trifluoromethylbenzyl group; Y means a ring structure connected to the rest of the molecule by an alkyl chain containing 1 or 2 carbon atoms, where appropriate, and this ring structure is a) optionally mono- or disubstituted phenyl group; b) 2-benzimidazolyl-, 2-imidazolyl- or 2- or 3-indolyl group, where one of the nitrogen atoms can optionally be substituted; (c) optionally mono- or disubstituted pyridinyl; or (d) optionally mono- or disubstituted naphthyl. HE
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30644901P | 2001-07-20 | 2001-07-20 | |
| FI20011560A FI116940B (en) | 2001-07-20 | 2001-07-20 | New N-pyrimidinyl para-aminobenzenesulfonamide derivatives as Alpha-2B adrenoceptor antagonists, useful for treating e.g. coronary heart disease, myocardial infarction, angina, restenosis and hypertension |
| PCT/FI2002/000643 WO2003008387A1 (en) | 2001-07-20 | 2002-07-22 | Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0401076A2 true HUP0401076A2 (en) | 2004-09-28 |
Family
ID=26161203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401076A HUP0401076A2 (en) | 2001-07-20 | 2002-07-22 | Alpha-2b-adrenoceptor antagonist compounds and their use for preparation of pharmaceutical compositions |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1417182A1 (en) |
| JP (1) | JP2004535467A (en) |
| CA (1) | CA2454187A1 (en) |
| HU (1) | HUP0401076A2 (en) |
| IL (1) | IL159511A0 (en) |
| MX (1) | MXPA04000615A (en) |
| NZ (1) | NZ530366A (en) |
| PL (1) | PL367040A1 (en) |
| RU (1) | RU2004105035A (en) |
| WO (1) | WO2003008387A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI118265B (en) * | 2004-01-15 | 2007-09-14 | Jurilab Ltd Oy | A method for detecting the risk of acute myocardial infarction and coronary heart disease |
| EP1861101B1 (en) | 2005-03-23 | 2012-10-24 | Klat-Pharma Animal Health GmbH | Use of amides of sulfadimidine for the treatment of intestinal diseases in veterinary science |
| WO2019081353A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituted imidazopyridine amides and use thereof |
| WO2020216669A1 (en) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenyl-substituted imidazopyridine amides and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2086544C1 (en) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity |
| US6150389A (en) * | 1994-07-11 | 2000-11-21 | Allergan Sales, Inc. | Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents |
| PL357872A1 (en) * | 2000-02-11 | 2004-07-26 | Oy Juvantia Pharma Ltd | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
| BR0110428A (en) * | 2000-04-28 | 2003-06-17 | Sankyo Co | A compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, uses of a compound or a pharmacologically acceptable salt thereof, a gamma modulator and a partial antagonist, agents that inhibit adipocyte differentiation, which enhances or restores osteogenic function, for the treatment or prevention of osteoporosis, which has ppar gamma modulating, blood sugar lowering activity, for the treatment or prevention of diabetes mellitus, and for the treatment or prevention |
-
2002
- 2002-07-22 RU RU2004105035/04A patent/RU2004105035A/en not_active Application Discontinuation
- 2002-07-22 PL PL02367040A patent/PL367040A1/en not_active Application Discontinuation
- 2002-07-22 WO PCT/FI2002/000643 patent/WO2003008387A1/en not_active Application Discontinuation
- 2002-07-22 CA CA002454187A patent/CA2454187A1/en not_active Abandoned
- 2002-07-22 JP JP2003513947A patent/JP2004535467A/en not_active Withdrawn
- 2002-07-22 EP EP02748902A patent/EP1417182A1/en not_active Withdrawn
- 2002-07-22 IL IL15951102A patent/IL159511A0/en unknown
- 2002-07-22 HU HU0401076A patent/HUP0401076A2/en unknown
- 2002-07-22 MX MXPA04000615A patent/MXPA04000615A/en unknown
- 2002-07-22 NZ NZ530366A patent/NZ530366A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL159511A0 (en) | 2004-06-01 |
| PL367040A1 (en) | 2005-02-21 |
| EP1417182A1 (en) | 2004-05-12 |
| CA2454187A1 (en) | 2003-01-30 |
| RU2004105035A (en) | 2005-06-27 |
| JP2004535467A (en) | 2004-11-25 |
| NZ530366A (en) | 2005-02-25 |
| MXPA04000615A (en) | 2004-04-20 |
| WO2003008387A1 (en) | 2003-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0401339A2 (en) | Novel 4-anilinoquinoline-3-carboxamides, process for their preparation and pharmaceutical compositions containing them | |
| HUP0303756A2 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them | |
| HUP0302480A2 (en) | Pyridinone derivatives for treatment of atherosclerosis, process for preparation thereof and pharmaceutical compositions containing the same | |
| HUP0402225A2 (en) | Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them | |
| HUP0002347A2 (en) | Use of hydantoin, oxazole and pyrrole derivatives for the preparation of pharmaceutical compositions inflammatory disease treating | |
| HUP0303084A2 (en) | 17 beta-carbothioate 17-alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents, process for their preparation and pharmaceutical compositions containing them | |
| HUP0401083A2 (en) | 4-amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for the preparation of the compounds | |
| HUP0302167A2 (en) | Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them | |
| HUP0303538A2 (en) | Thiazolyl inhibitors of tec family tyrosine kinases and pharmaceutical compositions containing them | |
| HUP9700992A2 (en) | 3-(piperid-4-yl)1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds, process for their preparation and pharmaceutical compositions containing them | |
| AR012593A1 (en) | SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| HUP0100156A2 (en) | Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions | |
| MY146669A (en) | Pyrazole derivatives for treating hiv | |
| HUP0400710A2 (en) | Thioether substituted imidazoquinolines, their use and pharmaceutical compositions containing them | |
| HUP0002112A2 (en) | Substituted 3-cyano quinolines, process for producing them and use of them and pharmaceutical compositions containing them | |
| HUP0303494A2 (en) | Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof | |
| HUP0401638A2 (en) | Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same | |
| HUP0302367A2 (en) | Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors and pharmaceutical compositions containing them | |
| DE60224172D1 (en) | FORMANILID DERIVATIVES AS BETA2 ADRENOR RECEPTOR AGONISTS | |
| HUP0400888A2 (en) | Substituted cyclohexane-1,4-diamine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0400250A2 (en) | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors, their preparation and their use for preparation of pharmaceutical compositions | |
| HUP0401235A2 (en) | Arylsulfonyl derivatives with 5-ht6 receptor affinity, process for producing them and pharmaceutical compositions containing them | |
| HUP0003413A2 (en) | New fused pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0003577A2 (en) | Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them | |
| MA27795A1 (en) | CYCLIC AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |